PATHOVACS INCORPORATED — Department of Defense STTR Phase II: CBD18A-001
PATHOVACS INCORPORATED — STTR Phase II award from Department of Defense.
Phase II STTR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $975,606 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Topic code CBD18A-001 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $975,606
- Agency
- Department of Defense · Office for Chemical and Biological Defense
- Program / Phase
- STTR · Phase II
- Topic
- CBD18A-001
- Solicitation
- 18.A
- NAICS
- —
- Place of performance
- IA
- Period
- 2020-09-01 → 2022-08-31
Description
Assays for accurate diagnosis of early stages of infection with biothreat agents, on the day of infection or within a few days of infection, will find wide use in both civilian and military applications These diagnostic assays, which are anticipated to be highly specific and sensitive, will add to the repertoire of tools of hospitals and clinics that serve our armed forces personnel deployed on the front lines in diverse geographical regions of the globe, as well infectious disease clinics that cater to civilian populations world-wide. In addition, such assays for early accurate diagnosis of infections caused by the above biothreat agents with the ability to wreak havoc in both humans and animals, will be very attractive for organizations involved in surveillance efforts for prompt and effective management of infections caused by these pathogens. The commercial market for such dual use diagnostic assays is therefore expected to be global.